10 results
424B5
XENE
Xenon Pharmaceuticals Inc
30 Nov 23
Prospectus supplement for primary offering
4:18pm
guidance documents continue in effect. The full impact of these policy changes and the wind-down of the public health emergency on the FDA and other
424B5
XENE
Xenon Pharmaceuticals Inc
29 Nov 23
Prospectus supplement for primary offering
5:05pm
declaration in May 2023, although some COVID-19 related guidance documents continue in effect. The full impact of these policy changes and the wind-down
8-K
EX-10.1
ky7qvl 35b60b
2 Dec 19
Neurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy
7:52am
8-K
EX-4.1
1af9vqfif
7 Aug 18
Entry into a Material Definitive Agreement
12:00am
S-1/A
EX-10.15
w1nl3eomvmpxs720x8
6 Oct 14
IPO registration (amended)
12:00am
- Prev
- 1
- Next